Home > La Jolla Pharmaceutical Salary

La Jolla Pharmaceutical Salary

  • 99
  • 41
  • 91
La Jolla Pharmaceutical average salary is $90,000, median salary is $90,000 with a salary range from $90,000 to $90,000.
La Jolla Pharmaceutical salaries are collected from government agencies and companies. Each salary is associated with a real job position. La Jolla Pharmaceutical salary statistics is not exclusive and is for reference only. They are presented "as is" and updated regularly.
Total 1 La Jolla Pharmaceutical Salaries. Sorted by Date, page 1
Ranked By:
Job Title Salaries City Year More info
Global Vice President Of Business Development 90,000-90,000 SAN DIEGO, CA, 92122 2015 La Jolla Pharmaceutical Global Vice President Of Business Development Salaries (1)
La Jolla Pharmaceutical SAN DIEGO, CA Salaries
Calculate how much you could earn

It's FREE. Based on your input and our analysis.     How we do it?

All fields are required for calculation accuracy.

  • We will send you an email to access your personalized report.
  • We won’t share your email address

La Jolla Pharmaceutical salary is full-time annual starting salary. Intern, contractor and hourly pay scale vary from regular exempt employee. Compensation depends on work experience, job location, bonus, benefits and other factors.

Real Jobs Salary - Salary List
Calculate Your Salary Ranking
La Jolla Pharmaceutical Jobs
Global Trial Management Assistant/Senior Administr
Collabera - La Jolla, CA
Program Specialist- Medical Customer Service
Corestaff - San Diego, CA
Regulatory Strategist II
Kelly Services - Andover, MA
See more La Jolla Pharmaceutical Jobs»
Search All Jobs

JobsOpenHiring – Find open jobs faster
La Jolla Pharmaceutica... Information
  • La Jolla Pharmaceutical Company
  • Industry: BioTech/Drugs
  • City: San Diego, CA
  • La Jolla Pharmaceutical Company (LJPC) is a biopharmaceutical company that is focused on the research and development of highly specific therapeutics for the treatment of certain life-threatening antibody-mediated diseases. These diseases, including autoimmuneconditions such as lupus and antibody-mediated stroke, are caused by abnormal B cell production of antibodies that attack healthy tissues. The Company's drug candidates, called Toleragens, are designed to treat the underlying cause of many antibody-mediated diseases without the severe, adverse side effects common to other treatments. The Companyis analyzing data from a Phase III clinical trial of its lupus drug candidate,LJP 394, and its clinical drug candidate